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AbstrACt
Introduction To investigate if β-adrenoreceptor blocking 
drug (β-blocker) prescription reduces the risk of knee or 
hip osteoarthritis, total joint replacement and analgesic 
prescription.
setting Primary care.
Methods and analysis This is a cohort study using 
data from the Clinical Practice Research Datalink. Two 
separate analyses will be performed. Study 1 will be 
on the association between β-blocker prescription and 
incident knee/hip osteoarthritis. Inclusion criteria will be 
age ≥40 years. Exposed participants will be those with 
≥2 continuous β-blocker prescriptions, and the index 
date will be the date of the first prescription of β-blocker. 
Unexposed participants will include up to four controls 
matched for age, sex, general practice surgery and 
propensity score for β-blocker prescription. Exclusion 
criteria will include contraindications to β-blockers, 
consultations for osteoarthritis or potent analgesic 
prescription before the index date. Outcomes will be 
knee osteoarthritis (primary outcome), hip osteoarthritis, 
knee pain and hip pain. Study 2 will be on the association 
between β-blocker prescription and total joint replacement 
and analgesic prescription in people with osteoarthritis. 
Inclusion criteria will be age ≥40 years, knee or hip 
osteoarthritis, and index date will be as in study 1. 
Unexposed participants will be as in study 1, additionally 
matched for consultation for knee or hip osteoarthritis 
prior to the index date. Exclusion criteria will include 
contraindications to β-blockers and osteoarthritis in other 
joints prior to the index date. Outcomes will be total knee 
replacement (primary outcome), total hip replacement and 
new analgesic prescription.
statistical analysis 
Kaplan-Meier curves will be plotted, and Cox proportional 
HRs and 95% CIs will be calculated. Stratified analysis 
will be performed by class of β-blocker, intrinsic 
sympathomimetic effect and indication(s) for prescription.
Ethics and dissemination This study was ethically 
approved by the Independent Scientific Advisory 
Committee of the Medicines and Healthcare Authority (Ref 
18_227R). The results of this study will be published in 
peer-reviewed journals and presented at conferences.
summary This prospective cohort study will evaluate 
the analgesic potential of commonly used drugs for 
osteoarthritis pain.
IntroduCtIon
Osteoarthritis is the most common form 
of arthritis worldwide. Its prevalence is 
increasing due to an ageing population and 
obesity epidemic.1 2 It is a leading cause of 
disability among older adults, with an esti-
mated lifetime risk of 25% and 45% for hip 
and knee osteoarthritis, respectively.3 4 There 
is no specific therapy for osteoarthritis, and 
management focuses on symptomatic treat-
ment, with total joint replacement reserved 
for those with severe symptomatic disease. 
However, analgesic and anti-inflamma-
tory drugs only have modest efficacy for 
strengths and limitations of this study
 ► The study has a large sample size and uses a na-
tionally representative data set.
 ► The study accounts for propensity score for β-ad-
renoreceptor drug prescription.
 ► The study compares the results of propensity score 
matching and adjustment analysis.
 ► A limitation is that this is a non-randomised study.
 ► Data on drug consumption were unavailable.
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osteoarthritis pain, with mean Western Ontario and 
McMaster Universities Arthritis Index improvement of 
3.99–11.24 across a spectrum of non-steroidal anti-in-
flammatory drugs (NSAIDs) and opioids.5 Apart from 
this, NSAIDs and cyclo-oxygenase II inhibitors increase 
the risk of gastrointestinal bleeding, acute kidney injury, 
chronic kidney disease, coronary heart disease, hyperten-
sion, stroke and congestive cardiac failure, and are asso-
ciated with increased cardiovascular mortality.6–18 These 
adverse effects are particularly important for people with 
osteoarthritis as they already have a high burden of cardio-
vascular comorbidities and risk factors.19 20 Consequently, 
healthcare practitioners are reluctant to prescribe 
NSAIDs as these patients are often on antiplatelet therapy 
for primary prevention or dual antiplatelet therapy 
following a cardiovascular event, meaning that prescrip-
tion of NSAIDs would expose patients to unacceptably 
high bleeding risk, and so the prescription of potent 
opioids for osteoarthritis pain has increased over the 
last decade.21 However, opioids induce dependence and 
increase the risk of falls, fractures and death.22–25 Thus, 
there is a need to develop safe, effective, well-tolerated, 
non-addictive analgesics to target osteoarthritis pain that 
can be prescribed safely to patients with cardiovascular 
comorbidities.
We recently demonstrated a negative association 
between self-reported β-adrenoreceptor blocking drug 
use and pain severity (adjusted OR (aOR) 0.68; 95% CI 
0.51 to 0.91) and use of opioid analgesics (aOR 0.73; 
95% CI 0.54 to 0.98) in community-dwelling adults with 
large-joint lower-limb osteoarthritis.26 We also found that 
each year of treatment with β-adrenoreceptor blocking 
medicines reduces the risk of joint pain (aOR 0.96; 
95%CI 0.93 to 0.99; p<0.004),26 and that other classes 
of antihypertensive medications, including α-adrenore-
ceptor blocking drugs, did not associate with joint pain 
or analgesic use.26
The purpose of this study is to explore the analgesic 
potential of β-adrenoreceptor blocking drugs and to 
identify the drug class that is most likely to have an anal-
gesic effect. The specific objectives are to examine the 
association between β-adrenoreceptor blocking drug 
prescription and incident knee osteoarthritis, incident 
hip osteoarthritis, incident knee pain, incident hip pain, 
analgesic prescription in knee or hip osteoarthritis, 
and total knee or hip joint replacement. We hypothe-
sise that patients prescribed β-adrenoreceptor blocking 
drugs are less likely to develop incident symptomatic 
lower limb osteoarthritis, and in those who have symp-
tomatic osteoarthritis to associate with fewer analgesic 
prescriptions and to slow the progression to total joint 
replacement due to the analgesic effect. Additionally, we 
will also explore data to identify the class of β-adrenore-




This is a cohort study.
Data source
Data from the Clinical Practice Research Datalink 
(CPRD) will be used in this study. Incepted in 1987, the 
CPRD is a longitudinal anonymised electronic database 
containing health records of >10 million people in the 
UK.27 CPRD participants are representative of the UK 
population in terms of age, sex and ethnicity.27 The CPRD 
contains details of diagnoses and primary care prescrip-
tions. The data are enhanced by linkage with hospitalisa-
tion (Hospital Episode Statistics) and mortality records 
(Office of National Statistics).
study population
All CPRD registered participants contributing accept-
able quality data in up-to-standard general practices 
(GP) between 1 January 1990 and 31 December 2017 are 
included. Two separate cohort studies will be performed.
Cohort study 1
Cohort study 1 will be on β-adrenoreceptor blocking 
drug prescription and incident osteoarthritis. Exposure 
will be ≥2 continuous prescriptions for β-adrenoreceptor 
blocking drugs, and will be further categorised according 
to duration of treatment (≤6 months, 7–12 months, 
12–24 months and >24 months). The outcomes will be 
knee osteoarthritis (primary), hip osteoarthritis, knee 
pain and hip pain.
Inclusion criteria
Exposed
 ► ≥2 continuous prescriptions of β-adrenoreceptor 
blocking drugs defined as two consecutive prescrip-
tions ≤60 days apart.
 ► Age ≥40 years on the date of the first of the two consec-
utive β-adrenoreceptor blocking drug prescriptions.
Unexposed
 ► Age (5-year age band based on year of birth), sex, GP 
surgery, year first registered in CPRD (±1 year) and 
propensity score for β-adrenoreceptor blocking drug 
prescription matched to the exposed participants.
Propensity for β-adrenoreceptor blocking drug prescription
As participants prescribed β-adrenoreceptor blocking 
drugs are likely to have comorbidities, be older and 
have a high body mass index (BMI), a propensity score 
for β-adrenoreceptor blocking drug prescription will be 
calculated using a cumulative logit regression model and 
including demographic factors and relevant diagnoses 
at any time prior to β-adrenoreceptor blocking drug 
prescription (box 1).
Exclusion criteria
Exclusion criteria will be consultation for any of the 
following prior to the index date:
 o
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box 1 List of potential variables to be included in the 
calculation of propensity score for β-adrenoreceptor 
prescription
demographic factors.
 ► Body mass index (WHO classification categories)*, smoking sta-
tus* and deprivation score (general practice-level Index of Multiple 
Deprivation Score).
Comorbidities.
 ► Hypertension, angina, myocardial infarction, congestive cardiac 
failure, atrial fibrillation, stroke, high cholesterol, chronic kidney 
disease, diabetes, anxiety, migraine, Charlson Comorbidity Index 
(excluding comorbidities in the propensity score) and duration in 
years of cardiovascular comorbidities prior to cohort entry.
drug prescriptions.
 ► Calcium channel blockers, ACE inhibitors, angiotensin II receptor 
antagonists, bendroflumethiazide, aldosterone antagonists, loop 
diuretics, alfa-adrenoreceptor blocking drugs, nitrates, nicorandil, 
aspirin, clopidogrel, statin, fibrate, vitamin K antagonists and 
non-steroidal anti-inflammatory drugs (in the progression cohort), 
and as a marker of severity of underlying disease at cohort entry 
the number of antihypertensive, antiarrhythmic or antianginal drugs 
prescribed in the 12-month period prior to cohort entry.
*Categorised as missing if not available.
 ► Osteoarthritis at any joint.
 ► Knee, hip, neck or back pain.
 ► Conditions causing joint damage or chronic pain: 
autoimmune inflammatory rheumatic diseases, such 
as rheumatoid arthritis, psoriatic arthritis, ankylosing 
spondylitis, lupus, polymyalgia rheumatica, gout, 
radiculopathy, neuropathy and fibromyalgia.
 ► Contraindications to prescription of β-adrenoreceptor 
blocking medicines: chronic obstructive pulmonary 
disease, asthma, peripheral vascular disease, heart 
block, aortic stenosis and hypertrophic obstructive 
cardiomyopathy.
 ► Two consecutive prescriptions for any opioid, any 
NSAID, gabapentin, pregabalin, duloxetine or 
amitriptyline prior to the index date.
 ► <1 year up-to-standard registration prior to index date 
to reduce the risk of prevalent cases (eg, with osteoar-
thritis) being classified as incident cases.28
The cohort entry date will be the index date. The unex-
posed participants will be allocated the index date of 
their matched exposed participant.
The cohort exit date will be the earliest of the date of 
the last prescription of β-adrenoreceptor blocking drug 
prescription, plus 4 weeks or a matched pseudo-exit date 
for the matched controls, date of the first outcome, date 
of death, transfer-out date, date of the last data collection 
or study end date (31 December 2017).
Cohort study 2
Cohort study 2 will be on β-adrenoreceptor blocking drug 
prescription and total joint replacement and analgesic 
use. The exposure will be as in cohort study 1.
The outcome will be total knee replacement (primary), 
total hip replacement and analgesic prescription: (1) 




 ► As in cohort study 1 above.
 ► Consultation for knee or hip osteoarthritis prior to 
the first of the two prescriptions for β-adrenoreceptor 
blocking drugs.
Unexposed
 ► As in cohort study 1, but with additional matching for 
prior consultation for knee or hip osteoarthritis to 
exposed participants.
Propensity for β-adrenoreceptor blocking drug prescription
This will be calculated as in cohort study 1. Additionally, 
propensity score will include hand osteoarthritis (inter-
phalangeal or thumb base osteoarthritis—a marker 
of generalised osteoarthritis), neck pain or back pain, 
spinal degenerative diseases (indicating osteoarthritis 
in the spine—a marker of generalised osteoarthritis), 
arthroscopic knee or hip surgery, number of analgesic 
prescriptions between the first consultation for knee/
hip osteoarthritis and β-adrenoreceptor blocking drug 
prescription, aspirin, statin and bisphosphonate, and 
glucosamine/chondroitin sulfate prescription in the 
12-month period prior to cohort entry, as these may affect 
knee or hip osteoarthritis progression.29–33
Exclusion criteria
Exclusion criteria will be previous consultation for any of 
the following prior to the first prescription of β-adrenore-
ceptor blocking drug:
 ► Osteoarthritis at any other joint.
 ► Neck or back pain.
 ► Conditions associated with joint damage or chronic 
pain (as above).
 ► Conditions contraindicating prescription of β-adreno-
receptor blocking medicines (as above).
 ► Previous knee or hip replacement.
 ► Knee or hip joint replacement within 3 months of 
the date of the first β-adrenoreceptor blocking drug 
prescription or matched index date in the unexposed 
participants. These will be excluded because we do 
not expect β-adrenoreceptor blocking drug prescrip-
tion to reduce total joint replacement rates immedi-
ately and may be commenced during preanaesthetic 
check-up.
 ► <1 year up-to-standard registration prior to the first 
qualifying prescription of β-adrenoreceptor blocking 
drug.28
 ► Additionally, participants who receive two consecu-
tive prescriptions for opioids, NSAIDs, gabapentin, 
pregabalin, duloxetine or amitriptyline prior to the 
index date will be excluded from the cohort when 
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examining the association between β-adrenore-
ceptor blocking drug prescription and new analgesic 
prescription.
The cohort entry and exit dates will be as in cohort 
study 1. Nearest neighbour matching (±0.2 SD) will be 
used to match exposed to unexposed participants.
statistical analysis
Covariate balance between matched exposed and unex-
posed participants will be examined. Unbalanced covari-
ates will be included in the model as separate covariates. 
Other covariates that do not influence exposure but 
influence outcomes or reflect health-seeking behaviour 
alone may be included in the model after evaluating their 
balance between exposed and unexposed groups. These 
are the following:
 ► Number of GP consultations in the 12-month period 
preceding cohort entry.
 ► Number of hospital outpatient referrals in the 
12-month period preceding cohort entry.
 ► Number of hospital admissions in the 12-month 
period preceding cohort entry.
 ► Total number of GP consultations for knee or hip 
injury prior to cohort entry.
 ► Non-osteoporotic fractures, defined as fractures in 
any bone except the femur, distal radius and verte-
brae, after the age of 18 years but before the age of 50 
years in women and 60 years in men. This is a surro-
gate for physically active occupation or lifestyle that 
may associate with incident osteoarthritis.
Participants will enter the cohort on the index date, and 
data will be censored at the earliest of an event, study end 
date (31 December 2017), date of death, transfer out of 
CPRD for all outcomes, and additionally date of the last 
prescription of β-adrenoreceptor blocking drugs, plus 
4 weeks (usual duration of GP prescription in the UK) 
for incident osteoarthritis, incident knee or hip pain, or 
new analgesic prescription. Given the reported effects of 
propranolol on pain sensitivity in patients with fibromy-
algia,34 we anticipate β-adrenoreceptor blocking drugs to 
have an analgesic effect in the short term, and outcome 
events >4 weeks after the date of the last β-adrenore-
ceptor blocking drug prescription will not be included in 
the analysis, except for total joint replacement which may 
be delayed due to a period of analgesia.
Time to event data in the exposed and unexposed 
groups will be compared using Kaplan-Meier survival 
curves. Schoenfeld residuals will be examined to see if 
survival curves meet the assumptions of the proportional 
hazard model. Cox proportional HRs and 95% CI will 
be calculated for each incident outcome using the first 
Read code for the event. Similarly, HRs will be calculated 
for new analgesic prescriptions, defined as prescription 
for NSAIDs, opioids, gabapentin and pregabalin, respec-
tively, in those exposed to β-adrenoreceptor blocking 
drugs, with unexposed as the referent.
The analysis will be stratified according to class of β-ad-
renoreceptor blocking drug used. A likelihood ratio test 
for interactions will be used to examine the hypothesis 
that the association between β-adrenoreceptor blocking 
medicines and incident osteoarthritis differs according 
to statin, aspirin or bisphosphonate prescription, as their 
use has been negatively associated with osteoarthritis.
sensitivity analyses
β-adrenoreceptor blocking drugs are used first line in the 
treatment of some conditions, for example, angina (first 
line according to the National Institute for Health and 
Care Excellence (NICE) guidelines) and atrial fibrilla-
tion,35 but may be reserved as add-on therapy for other 
conditions, for example, hypertension (third or fourth 
choice drug according to the NICE guidelines). More-
over, the magnitude of the association between indica-
tions for prescription of β-blockers and osteoarthritis 
varies.36 37 Therefore, analyses will be restricted to exposed 
and matched unexposed participants with (1) hyperten-
sion, (2) atrial flutter/fibrillation, (3) angina, (4) angina 
with underlying hypertension or atrial flutter/fibrilla-
tion, and (5) congestive cardiac failure. These sensitivity 
analyses will help account for residual confounding by 
underlying cardiovascular disease and its severity. Simi-
larly, total joint replacement rates may be affected by the 
severity of underlying disease for which the β-adrenore-
ceptor blocker was prescribed.
Further sensitivity analyses will be performed, restricting 
knee or hip pain as cohort entry criteria in cohort study 
2. This is because the Read codes for knee or hip osteo-
arthritis may only be allocated after several consulta-
tions for knee or hip pain. We will repeat our analysis 
using propensity score for β-adrenoreceptor blocking 
drug prescription as a covariate to allow us to compare 
the results from propensity score adjusted and matched 
analysis.
sample size
Incident knee osteoarthritis and hip osteoarthritis
The incidence of knee and hip osteoarthritis is 6.5 and 
2.1 per 1000 person-years in primary care-based Euro-
pean populations >40 years in age.1 Previous research 
suggests that 6.14% of patients registered in the CPRD are 
on β-adrenoreceptor blocking drugs, with over two-thirds 
on treatment for >10 years.38 Thus, for a cohort with 
one exposed and four unexposed participants, the total 
sample size required to detect an HR of 0.70 for devel-
oping knee osteoarthritis and hip osteoarthritis is 88 273 
(17 655 exposed) and 273 225 (54 645 exposed) partici-
pants, respectively, for a planned study with 80% power 
and 1% type I error.
Progression to joint replacement surgery
The incidence of total knee replacement in communi-
ty-dwelling adults with knee pain is 9 per 1000 person-years 
(Dr S Ingham, PhD thesis, University of Nottingham-
published on university website, 2012), and clinical 
experience suggests that hip osteoarthritis progresses 
more rapidly (AA, CM, MD). Thus, for a cohort with 
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one exposed and four unexposed participants, the total 
sample size required to detect an HR of 0.70 for total 
knee replacement in the exposed participants is 63 753 
with 80% power and 1% type I error. As 3.38% of commu-
nity-dwelling adults with clinically defined knee osteo-
arthritis are on β-adrenoreceptor blocking drugs (Knee 
Pain in the Community Study, 2014–2015, Professor 
Michael Doherty, unpublished data), and given a popu-
lation prevalence of knee pain of 20% in those over 40s, 
this gives a potentially eligible exposed population of 
40 560 from which to choose 12 755 exposed participants 
in the CPRD.
Plans for addressing missing data
We anticipate that both BMI and smoking will have 
missing data. Dummy variables will be created to repre-
sent missing data for smoking and BMI in the analyses. 
In addition, multiple imputation sensitivity analyses using 
chained equations will be carried out to explore any 
impact that assumptions regarding missing data will have 
had on any conclusions from the main analyses.
dIsCussIon
Findings from several studies suggest that β-adrenore-
ceptor blocking drugs may have an analgesic effect in 
osteoarthritis. β-adrenoreceptors are distributed widely in 
the central nervous system, and polymorphisms in β2-ad-
renoreceptor genes associate with fibromyalgia, chronic 
widespread pain and irritable bowel syndrome.39–42 They 
have demonstrated analgesic potential in randomised 
controlled trials in other painful conditions such as fibro-
myalgia, temporomandibular dysfunction and migraine, 
and in animal models of arthritis and pain.34 43–45 More-
over, β-adrenoreceptor blocking drugs also reduce the 
need for intraoperative anaesthetics and postoperative 
analgesia.46 This effect has been observed with the highly 
β1-adrenoreceptor selective drug esmolol, non-β1β2 
selective drugs such as propranolol, and drugs such as 
bupranolol which block the β3-adrenoreceptor.46 The 
mechanism by which β-adrenoreceptor blocking drugs 
provide analgesia includes heterodimerisation of β2-ad-
renoreceptors with µ-opioid receptors increasing the 
latter’s sensitivity,47 inhibitory effects on tetrodotox-
in-resistant sodium channels in the dorsal root ganglion 
neurons,48 and increased inhibitory neurotransmitter 
release in the spinal ganglions through a mechanism 
involving β1-adrenoreceptor-independent Ca2+ entry.45 If 
our study demonstrates analgesic potential for β-blockers, 
we will conduct clinical trials to confirm these findings. 
If our programme of research demonstrates meaningful 
analgesic effects of β-blockers for osteoarthritis pain, this 
class of drugs may be preferred in the treatment of cardio-
vascular diseases for people with comorbid symptomatic 
osteoarthritis.
Patient and public involvement in research
The idea for this study came from people with osteoar-
thritis who were concerned that the medicines they used 
for joint pain increased their risk of developing high 
blood pressure, angina, kidney damage, constipation, 
falls and so on. This was a serious problem as most of 
them already had high blood pressure or angina. They 
expressed the need for a new and safe analgesic that 
would not cause these side effects. They felt that it would 
be an additional bonus if the new analgesic could actu-
ally be used to treat any coexisting medical conditions, 
for example, high blood pressure. This unmet need led 
us to review the scientific literature and perform prelimi-
nary research.26 The results of this study were discussed at 
an Arthritis Research UK Pain Centre Patient and Public 
Involvement (PPI) meeting in July 2016. The PPI volun-
teers felt that further research is required to confirm the 
pain-relieving potential of β-blockers. The PPI group felt 
that the findings should be confirmed in another readily 
available large database before proceeding to a clinical 
trial.
dissemination
Findings of this study will be disseminated back to the 
Arthritis Research UK Pain Centre PPI group who helped 
develop this research. We will also convey the findings to 
people in the wider community. For this, we will actively 
engage universities’ existing routes of public communica-
tion, including social media engagement. The scientific 
outcomes of our research will be communicated to the 
clinical and academic audience via traditional routes of 
conference papers at national and international confer-
ences and open access research publications in presti-
gious, widely circulated medical journals.
Limitations of the study
Drugs available over the counter such as paracetamol are 
not recorded in the CPRD. It is possible that people on 
β-adrenoreceptor blocking drugs will consume less over-
the-counter NSAIDs and paracetamol. We are unable to 
measure this as these data are not recorded in the CPRD. 
As the CPRD does not have data on drug compliance, 
we cannot account for actual β-adrenoreceptor blocking 
drug consumption in a dose–response analysis. Similarly, 
despite our best efforts to minimise confounding, residual 
confounding may influence the estimates.
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